Vident Investment Advisory LLC boosted its holdings in shares of Qiagen NV (NASDAQ:QGEN) by 54.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 593,498 shares of the company’s stock after purchasing an additional 208,430 shares during the quarter. Vident Investment Advisory LLC owned about 0.26% of Qiagen worth $18,357,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also modified their holdings of QGEN. Citadel Advisors LLC raised its stake in Qiagen by 816.3% during the 4th quarter. Citadel Advisors LLC now owns 1,051,713 shares of the company’s stock valued at $32,529,000 after purchasing an additional 936,936 shares during the period. Atlanta Capital Management Co. L L C raised its stake in Qiagen by 210.1% during the 3rd quarter. Atlanta Capital Management Co. L L C now owns 1,314,274 shares of the company’s stock valued at $41,400,000 after purchasing an additional 890,454 shares during the period. Assenagon Asset Management S.A. raised its stake in Qiagen by 163.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 844,529 shares of the company’s stock valued at $26,326,000 after purchasing an additional 523,453 shares during the period. Systematic Financial Management LP bought a new stake in Qiagen during the 4th quarter valued at approximately $15,834,000. Finally, Russell Investments Group Ltd. raised its stake in Qiagen by 127.6% during the 3rd quarter. Russell Investments Group Ltd. now owns 652,285 shares of the company’s stock valued at $20,521,000 after purchasing an additional 365,732 shares during the period. 62.23% of the stock is currently owned by institutional investors.
Several analysts recently issued reports on the company. DZ Bank reissued a “neutral” rating on shares of Qiagen in a research note on Thursday. Deutsche Bank reissued a “buy” rating on shares of Qiagen in a research note on Monday, January 22nd. Commerzbank reissued a “buy” rating on shares of Qiagen in a research note on Thursday, February 1st. BidaskClub upgraded Qiagen from a “hold” rating to a “buy” rating in a report on Wednesday, February 21st. Finally, Zacks Investment Research upgraded Qiagen from a “sell” rating to a “hold” rating in a report on Tuesday, February 6th. Nine research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Qiagen currently has an average rating of “Hold” and an average price target of $35.33.
NASDAQ QGEN opened at $31.23 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.59 and a current ratio of 5.07. Qiagen NV has a 1-year low of $27.74 and a 1-year high of $36.34.
Qiagen (NASDAQ:QGEN) last released its quarterly earnings results on Wednesday, January 31st. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.42 by $0.01. The business had revenue of $396.86 million during the quarter, compared to analysts’ expectations of $394.48 million. Qiagen had a return on equity of 11.74% and a net margin of 2.85%. research analysts forecast that Qiagen NV will post 1.34 EPS for the current year.
Qiagen declared that its Board of Directors has approved a share buyback program on Wednesday, January 31st that authorizes the company to repurchase $200.00 million in shares. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock repurchase programs are generally an indication that the company’s board believes its shares are undervalued.
COPYRIGHT VIOLATION WARNING: “Vident Investment Advisory LLC Buys 208,430 Shares of Qiagen NV (QGEN)” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/07/vident-investment-advisory-llc-buys-208430-shares-of-qiagen-nv-qgen.html.
QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.